{"entity":{"id":"neovii","kind":"company","name":"Neovii","aka":["Neovii Biotech","Neovii Biotech GmbH","Neovii Pharmaceuticals AG"],"tldr":"Neovii is a Swiss company whose anti-T-lymphocyte globulin, Grafalon, is given before stem cell transplants to lower the risk of graft versus host disease.","summary":"Neovii, headquartered in Rapperswil-Jona, Switzerland, makes Grafalon (anti-T-lymphocyte globulin, previously ATG-Fresenius), a rabbit-derived polyclonal antibody used in conditioning before allogeneic haematopoietic stem cell transplantation to reduce graft versus host disease and rejection. It has led phase 3 transplant trials in leukaemia registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.neovii.com"},{"label":"ClinicalTrials.gov: trials led by Neovii","url":"https://clinicaltrials.gov/search?lead=Neovii"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["allogeneic-transplant"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Rapperswil-Jona","country":"CH","companyType":"biotech","website":"https://www.neovii.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/neovii/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"term":[{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/"}]}}